Pharmaceutics 2013, 5(1), 94-106; doi:10.3390/pharmaceutics5010094
Article

Safety Monitoring in Clinical Trials

Bin Yao* email, Li Zhuemail, Qi Jiangemail and H. Amy Xiaemail
Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA
* Author to whom correspondence should be addressed.
Received: 6 November 2012; in revised form: 9 January 2013 / Accepted: 10 January 2013 / Published: 17 January 2013
(This article belongs to the Special Issue Drug Safety and Pharmacovigilance)
PDF Full-text Download PDF Full-Text [442 KB, uploaded 17 January 2013 09:27 CET]
Abstract: Monitoring patient safety during clinical trials is a critical component throughout the drug development life-cycle. Pharmaceutical sponsors must work proactively and collaboratively with all stakeholders to ensure a systematic approach to safety monitoring. The regulatory landscape has evolved with increased requirements for risk management plans, risk evaluation and minimization strategies. As the industry transitions from passive to active safety surveillance activities, there will be greater demand for more comprehensive and innovative approaches that apply quantitative methods to accumulating data from all sources, ranging from the discovery and preclinical through clinical and post-approval stages. Statistical methods, especially those based on the Bayesian framework, are important tools to help provide objectivity and rigor to the safety monitoring process.
Keywords: clinical trial; safety monitoring; Data and Safety Monitoring Board (DSMB); sequential probability ratio test (SPRT); Bayesian methods

Article Statistics

Click here to load and display the download statistics.

Cite This Article

MDPI and ACS Style

Yao, B.; Zhu, L.; Jiang, Q.; Xia, H.A. Safety Monitoring in Clinical Trials. Pharmaceutics 2013, 5, 94-106.

AMA Style

Yao B, Zhu L, Jiang Q, Xia HA. Safety Monitoring in Clinical Trials. Pharmaceutics. 2013; 5(1):94-106.

Chicago/Turabian Style

Yao, Bin; Zhu, Li; Jiang, Qi; Xia, H. A. 2013. "Safety Monitoring in Clinical Trials." Pharmaceutics 5, no. 1: 94-106.

Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert